RT Journal Article
T1 Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study.
A1 Garcia-Broncano, Pilar
A1 Medrano, Luz Maria
A1 Berenguer, Juan
A1 Brochado-Kith, Oscar
A1 González-García, Juan
A1 Jiménez-Sousa, Ma Ángeles
A1 Quereda, Carmen
A1 Sanz, José
A1 Téllez, María Jesús
A1 Díaz, Laura
A1 JIménez, José Luis
A1 Resino, Salvador
A1 GESIDA 3603b Study Group, 
K1 Biomarkers
K1 Chronic hepatitis C
K1 HCV therapy
K1 HIV
K1 Immune activation
K1 Inflammation
AB There are a lack of consistency among articles in regards to the evolution of peripheral immune biomarkers after HCV therapy. We aimed to detect the most relevant changes in peripheral immune biomarkers among HIV/HCV-coinfected patients who achieved sustained virologic response (SVR) following peg-IFN-α/ribavirin therapy and to evaluate its normalization with respect to an HIV-monoinfected control group. We performed a prospective cohort study in 99 HIV/HCV-coinfected patients with samples at baseline (HIV/HCV-b-group) and at week 24 after SVR (HIV/HCV-f-group). We also used a control group of 39 HIV-monoinfected patients (HIV-group) negative for HCV and HBV infections, and who had undetectable HIV viral load and CD4+ >500 cells/mm3. Peripheral T cell subsets were assessed by flow cytometry and plasma biomarkers by immunoassays. HIV/HCV-coinfected patients had higher values of in IL-10, IL-4, IP-10, IL-8, IL-1β, IL-18, IL-6, IFN-γ, IL-12p70, TNF-α, sVCAM-1, sICAM-1, and sTNFR-1 than HIV control subjects, both at the beginning and at the end of follow-up. Moreover, three biomarkers (CD4+CD38+, telomere length, and IL-1RA) were normalized in relation to the control group at the end of follow-up (the HIV/HCV-b group had higher values and the HIV/HCV-f group had similar values as the HIV-group). Additionally, LPS, IL-2, and IL-17A levels were higher in the HIV/HCV-f group than the HIV-group (24 weeks after SVR). During the follow-up, HIV/HCV-coinfected patients had a significant decrease by the end of follow-up in CD8+CD45RA-CD28+, CD4+CD38+, CD4+CD25+CD127-/low, CD4+CD25+CD127-/low CD45RA-, FABP2, LBP, IP-10, sVCAM1. Only CD4+CD38+ was normalized. HIV/HCV-patients showed a slight improvement in the overall profile of immune biomarkers after achieving SVR.
YR 2019
FD 2019-10-01
LK https://hdl.handle.net/10668/26026
UL https://hdl.handle.net/10668/26026
LA en
DS RISalud
RD Apr 8, 2025